Adial Completes AD04 Demonstration Batch for Phase 3 Program

Adial Pharmaceuticals announced the successful completion of the demonstration batch production for AD04, its lead investigational drug for Alcohol Use Disorder. This milestone confirms the manufacturing process meets targeted specifications for the planned Phase 3 clinical program and matches the dissolution profile of the previous Phase 2 batch. The successful technical transfer to a new CDMO enables the production of clinical and registration batches, which are essential for conducting the upcoming clinical trial and updating the Investigational New Drug (IND) application with the FDA.